<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Use of <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> (<z:chebi fb="1" ids="35475">NSAIDs</z:chebi>) has been inversely associated with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>; however, the association within colorectal subsites or among higher risk individuals is understudied </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated <z:chebi fb="1" ids="35475">NSAID</z:chebi> use and colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> by subsite, and among individuals with a family history of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> in the National Institutes of Health-AARP Diet and Health Study </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Using Cox proportional hazards regression, we estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> incidence among 301,240 men and women (mean age 62.8 years); including 26,994 individuals with a first-degree relative with a history of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We accrued 3,894 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cases during 10 years of follow-up; 372 cases had a first-degree relative with <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Both aspirin and non-aspirin <z:chebi fb="1" ids="35475">NSAID</z:chebi> use reduced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk (HR for users compared with non-users=0.91, 95% CI: 0.85, 0.98; HR=0.82, 95% CI: 0.77, 0.87, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>Daily aspirin use reduced the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in the distal colon (HR=0.84, 95% CI: 0.71, 0.99) and rectum (HR=0.76, 95% CI: 0.64, 0.90); daily non-aspirin <z:chebi fb="1" ids="35475">NSAID</z:chebi> use reduced the risk of both proximal (HR=0.65, 95% CI: 0.54, 0.78) and distal <z:hpo ids='HP_0003003'>colon cancer</z:hpo> (HR=0.69, 95% CI: 0.55, 0.87), but not <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Among participants with a first-degree relative with <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, daily use of aspirin was associated with a decreased risk of <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> (HR=0.38, 95% CI: 0.19, 0.78), and daily use of non-aspirin <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> was associated with a decreased risk of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> (HR=0.49, 95% CI: 0.29, 0.82) </plain></SENT>
<SENT sid="7" pm="."><plain>No protective benefit for daily aspirin use and <z:hpo ids='HP_0003003'>colon cancer</z:hpo> or daily non-aspirin <z:chebi fb="1" ids="35475">NSAID</z:chebi> use and <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> was observed in this higher risk subgroup, although power was limited by small case numbers </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: <z:chebi fb="1" ids="35475">NSAID</z:chebi> use was associated with a reduced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk; the magnitude of this association differed between aspirin and non-aspirin <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Daily aspirin and non-aspirin <z:chebi fb="1" ids="35475">NSAID</z:chebi> use by individuals with a family history of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> significantly reduced the risk of rectal and <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, respectively </plain></SENT>
</text></document>